The Dental Chair as an Early Warning System for Neurodegeneration

The review, led by Alberto Herrero Babiloni and colleagues, synthesizes what is known about how neurological disease announces itself in the mouth before it announces itself anywhere else. The authors catalogue a recurring set of early signs: altered salivary flow, difficulty swallowing, burning sensations in the tongue or palate, unusual orofacial movements, tremors, and atypical facial pain. Individually, each of these is unremarkable — dry mouth is common, burning tongue is common, a quivering lip can be nothing. Collectively, and in the right pattern, they can be the opening notes of a disease that will not declare itself systemically for months or years. The review's central claim is that these signs are frequently misattributed to local or functional causes, thereby delaying diagnosis and care.

That is a meaningful claim, but it is also a measured one. This is a narrative review, not a randomized trial or a prospective screening study. It does not demonstrate that dental screening lowers time-to-diagnosis or improves outcomes. What it does — and what justifies taking it seriously — is assemble the clinical rationale: the orofacial system is densely innervated by cranial nerves whose function is among the earliest to degrade in several neurodegenerative diseases, and dentists see otherwise-healthy adults more regularly than almost any other clinician.

Parkinson's disease offers the cleanest illustration. Hyposalivation, drooling, subtle jaw tremor, and impaired tongue mobility can predate the classic motor triad. Alzheimer's disease can present in the dental chair as forgotten oral hygiene routines, missed appointments, or difficulty following chairside instructions — behavioral signals that a dentist who has known a patient for a decade is positioned to notice. ALS may first surface as fasciculations of the tongue or unexplained dysphagia. Multiple sclerosis can produce trigeminal neuralgia, facial numbness, or motor changes that masquerade as dental pain. The review organizes these manifestations by disease stage and functional impairment, with chairside screening tools intended to support recognition and referral rather than diagnosis.

The distinction matters. A dentist noticing tongue fasciculations and writing a referral to a neurologist is good medicine. A dentist telling a patient they may have ALS is not. The review is explicit that the appropriate output of a dental encounter is a question — directed to a physician — not an answer.

Honestly: moderate. The biological plausibility is strong, the clinical observations are consistent, and the orofacial manifestations described are well documented in the broader neurology literature. What is missing is the harder evidence that integrating dental observations into a screening pathway changes outcomes — earlier diagnosis, slower progression, better quality of life. The review acknowledges this gap implicitly by framing its contribution as practical tools for recognition rather than validated screening protocols.

Readers familiar with screening science will recognize the pattern. A symptom can be sensitive (it shows up early) without being specific (lots of other things cause it too). Burning mouth syndrome, hyposalivation, and orofacial pain are all common in adults without any neurodegenerative disease, often driven by medications, dehydration, anxiety, or perimenopause. The base-rate problem is real. A dentist who refers every patient with dry mouth to a neurologist will be wrong far more often than right. The review's value is in helping dentists recognize patterns and combinations that warrant a closer look, not isolated symptoms.

The authors also gesture toward what could strengthen the evidence base: progressive integration of artificial intelligence, machine learning, and other emerging technologies, including biosensors and salivary biomarker platforms. Saliva, in particular, is an attractive medium — accessible, repeatable, and biochemically rich. None of this is ready for the operatory yet. It is a direction of travel, not a current capability.

PinnacleLife readers are accustomed to thinking about screening as an active practice: not a thing that happens to you, but a thing you assemble. The 2026 review fits that frame without overreaching. It does not argue that everyone needs a neurology workup. It argues that the dental visit — already happening, already paid for, already on the calendar — is a checkpoint with more diagnostic potential than its current scope acknowledges. Realizing that potential requires improved training, interdisciplinary collaboration, and a willingness on the part of dentists, physicians, and patients to treat the mouth as continuous with the rest of the nervous system.

That is a reasonable ask. It is also, as of 2026, mostly aspirational. Most dentists are not trained to screen for neurodegenerative disease, most dental records are not structured to flag the relevant patterns, and most referral pathways from dentistry to neurology are informal at best. The review is, in part, a call to fix that. Until it is fixed, the practical move for a reader is smaller and more individual: know what your dentist is positioned to notice, give them the context to notice it, and treat any referral they make as worth following up on rather than dismissing as out of scope.

The dental chair will not replace the neurology clinic. But for a non-trivial number of people, it may be where the conversation starts. That is worth knowing — and worth, the next time you are reclined under that overhead light, mentioning anything that has changed.